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Nuclear Ftcfnr IV (NEW) in a hetctodimerlc DNA-bindina protein from Hetr cells, recclpnizing molecular ends rnd is identical la the autoantigen- 
ic target Ku, Wa have identified the two NFIV/Ku subunits, by comigration, in the ZD-geI database of transformed human amnion ccl1 (ANA) 
proteins. Weobserved that the large subunit of NFIV/Ku consists of at least 3 char&c wients that correspond to SSP IEFr 5705 (81.2 kDa, pl 
5.74), 6707 (81.2 kDa, pi 5.67) and 6706 (8i.9 kDa, pl 5.60) in the AMA ccrt~loguc. l”he relative amounts of the 2 major varianls (IEfs 5705 
and 6707) wus dcpcndcnt on the state of cell prolifcrstlon. Inhibition al DNA-synthesis by hydroxyurea al30 than@ the relalivc lcwls of the 
variants, whereas aphidicolin BP a rhymidinc block had na eflcct. Theso results auggcst P possible role for NFIVjKu in DNA replication. 
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1. INTRODUCTION 
Nuclear Factor IV was isolated as a HeLa nucIear 
protein chat recognized both ds- and ssDNA [I]. Unlike 
most DNA-binding proteins, NFIV needs molecular 
ends to recognize dsDNA. It recognizes either 3’-over- 
hanging, 5 ’ -overhanging or blunt ends, and after bind- 
ing it migrates towards inward positions on the DNA. 
At sufficiently high concentrations, the protein is able 
to form a regular dsDNA-multimeric protein complex. 
NFIV from HeLa cells is a hecerodimer consisting of a 
72 kDa and a 84 kDa subunit [l]. Cloning of a cDNA 
encoding the 84 kDa subunit, as well as immunological 
evidence have demonstrated that the proiein is identical 
to the autoantigen Ku [2]. The Ku protein is an aucoan- 
tigenic target in patients bearing sclecoderma, Graves’ 
disease and systemic lupus erychematosus [3,4,5 1. 
The cellular function of the protein is not known. Its 
ssDNA and dsDNA end-binding activity strongly sug- 
gests a role in DNA replication, repair or recombina- 
tion. Ku f6] or a related protein [7] has also been im- 
plied in transcriptional control, Here we have identified 
both NFIV/Ku subunits in the 2D-gel database of 
transformed human amnion cell (AMA) proteins [8] by 
a comigracion experiment. Furthermore, we present 
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studies on the relative abundance of different charge 
variants of NFIV/Ku as a function of cell proliferation. 
2. MATERIALS AND METHODS 
2.1 . Cells 
Transformed human amnion cells (AMA) were grown in Dulbec- 
co’s modified Eagle’s medium containig IO’?% fetal serum and an- 
tibiotics (penicillin, 100 U/inl; streptomycin 5O,~g/ml). 
2.2, 2Dqel elecrrophoresis 
Standardized 2D (IEF-SDS) gel electrophoresis was performed as 
described [8,9). 
2,3, Inhibition of DPJA synthesis 
Mitotic AMA cells were obtained by mechanical detachment essen- 
tially as described [iO]$ Inhibition of DNA synthesis was accomplish- 
ed by addition of aphidicolin (5 pg/ml), hydroxyurea (10 mM) or 
thymidine (2 mM) 1 h after plating of the cells. Proteins were labelled 
for 1.5 h with [‘%]methionine starting lS.5 h after plating. This 
period corresponds to S-phase in non-treated cells [I 11. Subsequently 
the cells were collected and resuspended in lysis buffer [9], 
2.4, IVFI V/Ku preparalions 
NFIV/Ku was isolated from HeLa cells as described [l] using ion- 
exchange and ssDNA- and dsDNA_affinity chromatography. The 
resulting preparation ismore than 95% pure as judged by ZD-gel elec- 
trophoresis and silver staining. 
3. IRESULTS 
3.1. 2l3 pi anaiysis of NFI Fr 
We analyzed purified NFIV on a 2D (IEF-SDS) gel. 
As shown in Fig. lA, silver staining of the gel revealed 
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Fig. 1. Nuclear Factor IV largcsubunit comigratcu with proteins IEl: 5705 and IEF6707. Purified NPlV was imnlyrcd on R 2D (IEF4DS) gel (A). 
Lnryc and small subunit isoforms arc indicated by arrows. In R separate experiment purified NFlV was mixed with s [%]mcthioninc lnbfllcd AMA 
protein extract and nnalyrcd on a 2D (IEF-SDS) gc!. (B) Shows part of the gel nfter silver staining. The oddirional spots nrc derived from proteins 
in the AMA extract. (C) Shows the same part of the gel after autoradiography. The numbering of the proteins is according to [8Js 
that the protein consists of a series of polypeptides. The 
large subunit resolves into 3 polypeptides with nearly 
identical apparent molecular weights, but with different 
pl. The small subunit, on the other hand, is less well 
resolved, and may also consist of different modified 
forms (Fig, 1A). 
3.2. Assignment of NFIV subunits to proteins in the 
AM.4 2D-gel protein database 
In order to identify NFIV in the AMA protein 
database [a], we mixed [?S]methionine labelled protein 
extract from AMA cells with purified NFIV. Silver 
staining of the gel (Fig. IB) followed by autoradio- 
graphy revealed that the 3 spots which constitute the 
large subunit comigrate with a series of 3 radiolabelled 
proteins (Fig. lC), which corresponded to SSP IEFs 
5705 (81.2 kDa, pI 5.74), 6707 (81.2 kDa, ~15.67) and 
6706 (81.9 kDa, pl 5.60) in the AMA 2D-gel protein 
database [a]. SSP IEFs 5785 and 6707 are also known as 
primatin [$] and correspond to IEFs 8230 and 8231 in 
the MeLa protein catalogue [ 121. 
The small subunit is not visible in this part of the gel, 
but careful analysis of the silver-stained gel and the 
autoradiograph revealed that it is identical to AMA 
protein SSP IEF 2505. It has an apparent Mr of 64.2 
kDa and a pl of 6.77. 
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3.3. Proliferation-specific distribution of charge 
variants of the large NFIV subunit 
Two charge variants of the large subunit (proteins 
IEF 5905 and 6909) have been studied previously, and 
were referred to as 8230 and 823 1, respectively [ 13,141. 
Their identical mobility in a SDS-gel, as well as their 
reactivity with the same monoclonal antibody, already 
suggested chat they correspond to charge+ariants of a 
single polypeptide. Interestingly, the relative levels of 
the 2 protein variants differ considerably between 
quiescent and transformed cells, In quiescent human 
fibroblasts (MRC-5) IEF 6709 is present at 2.3-fold 
higher levels than the more basic variant IEF 5705. In 
proliferating normal MRC-5 cells this ratio is about 1.2, 
while in their SV40-transformed counterparts the ratio 
is 0.6. The results indicate that - dependent on growth 
- the relative amounts of the charge variants change. In 
this analysis [13], the other protein variant (SSP IEF 
6706) was not examined, because it is synthesized at 
much lower levels, and therefore undetectable atthe ex- 
posure times used. 
The apparent dependence on the state of cellular pro- 
liferation suggested that the protein may be modified 
during progression through the cell cycle. Analysis of 
the [35S]methionine labelled proteins synthesized 




Fig. 2. Synthesis ofchsrgc variants IEP 5705 and IEFG707 (indicated 
by triangles) in normnl and hydroxyurea-treated transformed human 
amnion (AMA) cells (A) Shows the pattern of synthesis of 
[“S]mcthionine Inbelled proteins in untreated AMA cells, (U) Shows 
the piWern of synthesis in hydroxyurca-treated cells. 
difference in the ratio of the 2 major variants (SSP IEFs 
5705, 6707) of the large subunit (results not shown). In 
view of the DNA-binding properties of NFIV/Ku we in- 
vestigated whether changes in the 2 major variants of 
the large subunit occur in cells arrested at the Gl/S 
transition border of the cell cycle. For this purpose, syn- 
chronized AMA cells were treated with either aphidi- 
colin, high concentrations of thymidine or hydroxyurea 
(Fig. 2). The drugs were administered at Gl-phase, 1 h 
after plating mitotic cells. Proteins were then labelled 
with [3SS]methionine 15.5-17 h after plating, This time- 
span corresponds to S-phase in non-treated cells [1 11. 
Control cells, which did not receive inhibitors, syn- 
thesize high levels of IEF 5705 and low levels of IEF 
6707, characteristic of the transformed cells. Thymidine 
ancl aphidicolin-treated cells exhibit an almost identical 
pattern of protein synthesis (data not shown). 
However, the cells that received hydroxyurea have a 
low IEF 5707 level and a high IEF 6707 level (Fig. 2), 
just like the quiescent cells. 
4. DISCUSSION 
We have identified Nueierrr Factor IV (NFIV), which 
is identical to the Ku autoantigen [2J, in the AMA ID- 
ge! protein database [SJ. The purified pratein wr- 
responds to SSP IEF 5705, 6707 and 6706 a~ charge 
wriantr eonatituting the large ?rubunit, QS well BJE SSP 
IEF 2505 corresponding to thr. small subunit, 
The nature of the modifiesrion which distinguishes 
the charge vsrianrs is not known, Labelling with 
[Z*PJorthophosphate ‘invim’ could nor be derected for 
SSPs 5705 and 6707 [8,13]. However, phosphoamino- 
acid analysis of the Ku protein has indicated thnt both 
the small and large subunit of Ku may bc phosphory- 
lated at serine residues [6), In addition, a DNA= 
dependent protein kinnse was rcccntly found that could 
phoophorylarc the Ku autoantigen ‘in vitro’ [IS]. The 
reason for this discrepancy is at present unknown. Acs 
cording to our data [8,13J it is possible that the dif- 
fwencc between the IEF 5705 and 6707 polypcptides 
may be due to post-translational modifications other 
than phosphorylation. The detection of another large 
subunit variant (SSP IEF 6706) suggests that multiple 
modifications are possible. 
Proteins 5705 and 6707 previously attracted attention 
because the relative level of the charge variants ap- 
peared to be influenced by the proliferative state of the 
cell [ 131. We show here that in hydroxyurea treated cells 
the pattern of synthesis of the charge variants is altered. 
In contrast, aphidicolin treatment and high concentra- 
tions of thymidine do not influence the relative amount 
of synthesis of the charge variants. The drugs all cause 
accumulation of cells in and around the Gl/S boun- 
dary, suggesting that the modification of the large 
subunit may take place close to the onset of DNA 
replication. 
The target of hydroxyurea isribonucleotide reductase 
[16], the key enzyme that catalyzes the reduction of 
ribonucleotides to deoxyribonucleotides. High concen- 
trations of thymidine disturb, by allosteric interactions, 
the coordinated synthesis of deoxyribonucleotides [17]. 
Aphidicolin is a competitive inhibitor of DNA poly- 
merases (Y and 6 [lS]. Presently, we do not understand 
why the various inhibitors show such contrasting effects 
on the synthesis of the charge variants. 
Immunofluorescence studies using a monoclonal an- 
tibody (mAb lC4ClO) that recognizes both charge 
variants have revealed that the protein is present in the 
nuclei, especially in the nucleoli [13]. In addition, 
microinjection of mAb lC4ClO in the cytoplasm of 
cells expressing NFIV leads to nuclear and nucleolar ac- 
cumulation [141. Cells that are about to enter M-phase 
show some antigen in the cytoplasm (data not shown), 
while M-phase staining is most apparent in the area sur- 
roun.ding the chromosomes, which agrees well with the 
immunofluorescence data on the Ku antigen. It should 
be stressed however that immunofluorcscence data on 
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the Ku nutowntigcn have yielded conflicting resultr con- 
cerning rho nucleolar staining [3,4,19,20,21], OKC way 
to reconcile these data is to assume that NFIVlKu has 
8 cell stage-specific interaction with other cellular corn- 
poncnts, thereby shlefding epitopes recognized by some 
of the available rntibodica, 
The analysis of NFIV/Ku in the human AMA 2D4tei 
protein database has provided us with data concerning 
proliferation= and cell cycle-specific modifications of 
the polypeptide, In combination with biochemical data 
on the nucleic acid binding properties of NFIV [I J, it is 
suggested that NFIV may play a role in DNA replica- 
tion. 
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